Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

iTeos Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 17, 2025. As of April 21, 2025, the record date for the Annual Meeting, there were 38,273,795 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. There were 33,554,964 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which represented 87.67% of the outstanding shares entitled to vote at the Annual Meeting, which constituted a quorum for the transaction of business. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 24, 2025: (i) to elect Tony Ho, Robert Iannone and Ann D. Rhoades as Class II directors, each to serve for a three-year term expiring at the Company's 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal and (ii) to ratify the appointment of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results for the Annual Meeting are as follows:

The Company's stockholders elected each of the Class II director nominees. The votes cast at the Annual Meeting were as follows:

The Company's stockholders approved the ratification of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public account firm. The votes cast at the Annual Meeting were as follows:

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.